Evidence map›Paper›PMID 31918665›Full record

SynthesisBMC cardiovascular disorders2020

Trimethylamine-N-oxide has prognostic value in coronary heart disease: a meta-analysis and dose-response analysis.

Miao-En Yao, Peng-Da Liao, Xu-Jie Zhao, Lei Wang

Open access · goldAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cardiovascular disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 6 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 6 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. New Modifiable Risk Factors Influencing Coronary Artery Disease Severity.International journal of molecular sciences · 2024
    Review
  20. Role of Trimethylamine N-Oxide in Heart Failure.Reviews in cardiovascular medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Miao-En YaoLongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
Peng-Da LiaoDepartment of Critical Care Medicine, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China.
Xu-Jie ZhaoDepartment of Critical Care Medicine, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China.
Lei WangDepartment of Cardiovascular Medicine, 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, NO. 111 Dade Road, Yue-Xiu District, Guangzhou, 510120, China. Dr.wanglei@139.com.ORCID 0000-0001-5349-6298
Guangzhou University of Chinese Medicine · CN

Funding

Special support plan for training high level talents in Guangdong Province 2015TQ01R588the Discipline of Integrated Chinese and Western Medicine in Guangzhou University of Chinese Medicine YN2015MS21, YN2019MJ15the Guangdong Natural Science Funds for Distinguished Young Scholars 2015A030306049the National Natural Science Foundation of China 81573708
6 · The paper itself

Abstract

backgroundPrevious clinical studies have suggested that trimethylamine-N-oxide (TMAO) could contribute to the development of atherosclerosis cardiovascular disease. However, the synthetic analysis in coronary heart disease (CHD) was not yet performed. We aimed to clarify the relationship between elevated plasma concentrations of TMAO and the incidence of major adverse cardiovascular events (MACE) in CHD patients.

methodsMeta-analysis and dose-response analysis of hazard ratio data from prospective observational studies reporting on the association between TMAO plasma concentrations and the incidence of MACE in patients with CHD were conducted.

resultsOf the 2369 published articles identified in the search, seven papers, with data from nine cohort studies (10,301 patients), were included in the meta-analysis. Combined data showed that elevated plasma TMAO concentrations could increase 58% higher risk of MACE in patients with CHD (hazard ratios [HR]: 1.58; 95% confidence interval [CI] = 1.35-1.84, P = 0.000). For follow-up ≥ 1 year, it was associated with 62% higher risk of MACE in patients with longer-term than shorter-term (HR for follow-up ≥ 4 years: 1.96; 95% CI = 1.52-2.52 vs one to 3 years: 1.34; 95% CI = 1.26-1.43, P = 0.004). The dose-response analysis revealed a 'J' shaped association between TMAO concentration and the incidence of MACE (P = 0.033), with the concentration above 5.1 μmol/L being associated with HR of > 1.

conclusionsElevated levels of TMAO are associated with an increased incidence of MACE in patients with CHD. TMAO concentration of 5.1 μmol/L may be a cut-off value for prognosis.

Indexed as

AgedAged, 80 and overBiomarkersCoronary DiseaseFemaleHumansIncidenceMaleMethylaminesMiddle AgedObservational Studies as TopicPrognosisUp-RegulationBiomarkersMethylaminestrimethyloxamineCoronary diseaseDifferential thresholdDose-response relationshipMeta-analysis as topicTrimethyloxamine

Identifiers

PMID31918665
PMCPMC6953212
OpenAlexW3005648150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.